Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2023 - 2

MQ, Institut für Klinische Chemie, Universitätsspital Zürich, 8091 Zürich
Telefon 044/255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B1 Strep A Test, B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics
The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 11.7.2023

Dr. R. Fried
Survey Director

.

INR



QUALAB tolerance : 15 %

INR ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	17	94.1	5.9	0.0	1.57	5.8	e
2	Neoplastin R	16	100.0	0.0	0.0	1.66	2.9	e
3	Neoplastin Plus	7	100.0	0.0	0.0	2.04	5.6	e*
4	Recombiplastin 2G	11	90.9	0.0	9.1	1.71	5.2	e
5	Other methods	13	100.0	0.0	0.0	1.64	4.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen OA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	9	100.0	0.0	0.0	1.10	6.2	e*
2	Stago/STA	18	100.0	0.0	0.0	1.14	6.1	e
3	Fibrinogen Q.F.A.	7	100.0	0.0	0.0	1.15	6.6	a
4	Other methods	4	100.0	0.0	0.0	1.17	8.0	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	8	100.0	0.0	0.0	36.1	11.6	e*
2	Pathromtin SL	7	100.0	0.0	0.0	65.5	6.2	e
3	Stago/STA	21	100.0	0.0	0.0	52.3	7.2	e
4	aPTT-SP	7	100.0	0.0	0.0	40.8	5.7	e
5	Other methods	9	100.0	0.0	0.0	41.9	12.8	e*

INR CoaguChek



QUALAB tolerance : 15 %

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	800	98.6	0.6	0.8	3.0	4.0	e

Prothrombin time NT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	11	100.0	0.0	0.0	100	0.9	e
2	Neoplastin R	15	100.0	0.0	0.0	98	2.5	e
3	Neoplastin Plus	6	100.0	0.0	0.0	91	4.8	e*
4	Recombiplastin 2G	10	100.0	0.0	0.0	99	1.9	e
5	Other methods	14	100.0	0.0	0.0	100	0.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen N



QUALAB tolerance : 15 %

Fibrinogen N (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	7	100.0	0.0	0.0	2.89	8.6	e*
2	Stago/STA	18	100.0	0.0	0.0	2.87	4.0	e
3	Fibrinogen Q.F.A.	10	100.0	0.0	0.0	2.78	6.6	e*
4	Fib Clauss (IL)	6	100.0	0.0	0.0	2.59	2.8	e
5	Other methods	7	100.0	0.0	0.0	2.75	7.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	96.6	6.0	e

aPTT N



QUALAB tolerance : 25 %

aPTT N (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	8	100.0	0.0	0.0	22.1	5.1	e
2	Pathromtin SL	4	100.0	0.0	0.0	39.1	7.9	e*
3	Stago/STA	22	100.0	0.0	0.0	31.9	5.9	e
4	aPTT-SP	12	100.0	0.0	0.0	25.3	6.3	e
5	Other methods	8	100.0	0.0	0.0	33.5	14.6	e*

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	100.0	6.5	e

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	99	1.6	e
2	Neoplastin R	14	100.0	0.0	0.0	98	3.0	e
3	Recombiplastin 2G	12	100.0	0.0	0.0	99	3.1	e
4	Other methods	10	100.0	0.0	0.0	97	2.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	10	100.0	0.0	0.0	0.27	9.9	e*
2	ACL	21	95.2	4.8	0.0	0.43	11.5	e*
3	Other methods	12	100.0	0.0	0.0	0.51	10.1	e*

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.26	7.8	e*
2	Stago/STA	15	100.0	0.0	0.0	3.36	5.2	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	3.25	3.9	e
4	Other methods	9	100.0	0.0	0.0	3.23	5.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	44.3	3.1	e
2	Actin FSL	4	100.0	0.0	0.0	44.0	4.3	e
3	Stago/STA	14	100.0	0.0	0.0	75.3	9.1	e
4	aPTT-SP	13	100.0	0.0	0.0	70.7	7.4	e
5	Other methods	7	85.7	14.3	0.0	55.3	14.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

D-dimer



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	STA Liatest	17	100.0	0.0	0.0	2.98	3.7	e
2	Siemens Innovance	13	100.0	0.0	0.0	5.09	4.8	e
3	Pathfast	11	100.0	0.0	0.0	5.00	0.0	e
4	ACL	11	100.0	0.0	0.0	4.51	3.4	e
5	AQT 90 FLEX	6	100.0	0.0	0.0	2.02	6.5	e*
6	VIDAS	18	94.4	5.6	0.0	3.22	9.9	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

CoaguChek APTT



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	7	100.0	0.0	0.0	90.5	8.3	e*

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1459	98.5	0.8	0.7	2.0	3.6	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	7	100.0	0.0	0.0	5.3	6.7	e*

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MicroINR	132	81.0	2.3	16.7	2.1	8.0	e

INR Xprecia



QUALAB tolerance : 15 %

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	50	96.0	2.0	2.0	2.9	4.8	e

INR Lumira Dx



QUALAB tolerance : 15 %

INR Lumira Dx ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	12	100.0	0.0	0.0	4.4	8.9	e*

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	9	100.0	0.0	0.0	0.57	7.7	a
2	ACL	14	100.0	0.0	0.0	0.62	10.1	e*
3	Other methods	16	100.0	0.0	0.0	0.75	9.8	e*

Anti-FXa (Rivaroxaban)

MQ tolerance : 20 %

Anti-FXa (Rivaroxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	9	100.0	0.0	0.0	303.00	4.6	e
2	ACL	8	100.0	0.0	0.0	296.25	8.6	e*
3	Other methods	4	100.0	0.0	0.0	264.42	8.1	e*

Anti-FXa (Apixaban)

MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ACL	4	100.0	0.0	0.0	296.70	6.2	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	12	100.0	0.0	0.0	100.1	3.4	e
2	Cyanmethemoglobin	17	88.2	5.9	5.9	100.1	4.2	e
3	Sysmex X	50	100.0	0.0	0.0	101.0	1.8	e
4	Hemocue	399	94.7	1.3	4.0	101.0	2.4	e
5	Hemocontrol	17	94.1	0.0	5.9	101.5	1.4	e
6	DiaSpect	15	86.6	6.7	6.7	106.3	5.4	e*
7	Sysmex	7	100.0	0.0	0.0	101.0	2.9	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	115	93.9	2.6	3.5	100.6	2.9	e
2	Sysmex PocH - 100i	195	94.9	0.5	4.6	99.0	2.2	e
3	Sysmex XP 300	613	97.8	0.2	2.0	99.9	1.8	e
4	Mythic	240	94.1	1.7	4.2	98.4	2.9	e
5	Sysmex XQ-320	78	96.2	0.0	3.8	101.8	1.4	e
6	Swelab	27	100.0	0.0	0.0	104.5	1.8	e
7	Medonic	4	100.0	0.0	0.0	101.0	5.0	e*
8	Celltac Alpha (Nihon	87	98.9	0.0	1.1	103.4	2.2	e
9	Samsung HC10	11	100.0	0.0	0.0	99.5	2.6	e
10	Micros 60	69	91.3	2.9	5.8	99.1	3.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	10	90.0	0.0	10.0	0.27	3.1	e
2	Sysmex X	50	100.0	0.0	0.0	0.29	2.7	e
3	Sysmex	7	100.0	0.0	0.0	0.29	3.7	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	79	98.7	0.0	1.3	0.28	2.7	e
2	Sysmex KX21	115	95.6	0.9	3.5	0.27	2.9	e
3	Sysmex PocH - 100i	194	94.4	1.0	4.6	0.29	3.2	e
4	Sysmex XP 300	613	97.7	0.3	2.0	0.27	2.2	e
5	Mythic	241	92.1	2.9	5.0	0.29	3.5	e
6	Swelab	27	96.3	3.7	0.0	0.29	3.6	e
7	Medonic	4	75.0	25.0	0.0	0.28	7.0	e*
8	Celltac Alpha (Nihon	87	87.4	5.7	6.9	0.29	4.1	e
9	Samsung HC10	11	100.0	0.0	0.0	0.30	2.8	e
10	Micros 60	69	85.5	8.7	5.8	0.26	4.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	10	100.0	0.0	0.0	3.25	3.2	e
2	Sysmex X	50	100.0	0.0	0.0	3.22	1.7	e
3	Sysmex	7	100.0	0.0	0.0	3.20	2.8	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	79	97.4	1.3	1.3	3.34	4.4	e
2	Sysmex KX21	115	97.4	0.9	1.7	3.26	4.5	e
3	Sysmex PocH - 100i	194	96.4	1.5	2.1	3.34	4.4	e
4	Sysmex XP 300	614	97.9	1.1	1.0	3.26	4.1	e
5	Mythic	241	96.2	2.1	1.7	3.20	5.8	e
6	Swelab	27	100.0	0.0	0.0	3.25	2.8	e
7	Medonic	4	100.0	0.0	0.0	3.11	5.2	e
8	Celltac Alpha (Nihon	87	97.8	1.1	1.1	3.33	4.5	e
9	Samsung HC10	11	100.0	0.0	0.0	3.28	2.9	e
10	Micros 60	69	94.3	1.4	4.3	3.16	6.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	10	80.0	0.0	20.0	4.49	9.9	e*
2	Microscopic	8	75.0	0.0	25.0	4.10	7.2	e
3	Sysmex X	50	100.0	0.0	0.0	4.69	8.3	e
4	Sysmex	7	85.7	14.3	0.0	4.30	17.7	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	79	96.2	2.5	1.3	4.68	8.5	e
2	Sysmex KX21	115	95.6	0.9	3.5	4.47	8.5	e
3	Sysmex PocH - 100i	194	96.4	0.0	3.6	4.39	9.0	e
4	Sysmex XP 300	613	98.5	0.7	0.8	4.51	8.0	e
5	Mythic	239	97.0	1.3	1.7	4.45	9.1	e
6	Swelab	27	92.6	3.7	3.7	4.43	10.4	e
7	Medonic	4	100.0	0.0	0.0	4.35	7.2	e*
8	Celltac Alpha (Nihon	86	97.7	2.3	0.0	4.57	9.1	e
9	Samsung HC10	11	90.9	9.1	0.0	4.62	10.7	e*
10	Micros 60	69	94.2	2.9	2.9	4.18	10.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	9	100.0	0.0	0.0	213.0	7.9	e
2	Microscopic	5	80.0	0.0	20.0	185.0	6.0	e
3	Sysmex X	48	100.0	0.0	0.0	200.6	6.9	e
4	Sysmex	7	85.7	14.3	0.0	200.0	13.0	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	79	94.9	5.1	0.0	197.4	9.9	e
2	Sysmex KX21	115	99.1	0.9	0.0	210.1	8.6	e
3	Sysmex PocH - 100i	194	96.4	2.1	1.5	205.9	7.7	e
4	Sysmex XP 300	613	96.6	1.3	2.1	213.0	7.0	e
5	Mythic	241	95.0	2.9	2.1	197.4	10.3	e
6	Swelab	27	96.3	0.0	3.7	203.3	7.0	e
7	Medonic	4	100.0	0.0	0.0	206.0	5.9	e
8	Celltac Alpha (Nihon	87	96.6	3.4	0.0	213.7	9.7	e
9	Samsung HC10	11	100.0	0.0	0.0	225.6	6.5	e
10	Micros 60	69	88.4	5.8	5.8	195.6	11.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	206	95.6	1.5	2.9	101.7	3.3	e
2	Abx Micros	60	95.0	0.0	5.0	101.8	2.6	e
3	Microsemi	881	97.0	0.5	2.5	103.6	1.9	e

Hematocrit H2



QUALAB tolerance : 9 %

Hematocrit H2 (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	206	95.2	1.9	2.9	0.30	4.0	e
2	Abx Micros	60	95.0	1.7	3.3	0.27	3.5	e
3	Microsemi	881	95.5	1.1	3.4	0.27	2.8	e

Leucocytes H2



QUALAB tolerance : 25 %

Leucocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	206	96.6	2.4	1.0	5.07	9.1	e
2	Abx Micros	60	93.3	1.7	5.0	5.01	10.6	e
3	Microsemi	880	97.9	1.0	1.1	5.20	8.2	e

Thrombocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	206	95.7	1.9	2.4	223.5	8.9	e
2	Abx Micros	60	90.0	1.7	8.3	212.2	9.4	e
3	Microsemi	881	95.0	2.3	2.7	216.0	8.6	e

Erythrocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	206	97.6	0.5	1.9	3.25	4.5	e
2	Abx Micros	60	98.3	1.7	0.0	3.31	6.7	e
3	Microsemi	880	97.2	0.9	1.9	3.24	4.3	e

CRP H2



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	188	91.5	3.2	5.3	39.0	9.7	e
2	Microsemi	869	92.7	2.5	4.8	45.8	9.0	e
3	Abx Micros	12	91.7	0.0	8.3	46.4	9.6	e*
4	ABX Micros CRP200	46	84.8	13.0	2.2	39.9	13.9	e

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	12	100.0	0.0	0.0	193.0	3.3	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	19	89.4	5.3	5.3	0.56	4.0	e
2	EPOC	10	90.0	10.0	0.0	0.51	4.9	e*

Hemoglobin



QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	100.0	0.0	0.0	131.1	1.3	e
2	Advia	4	100.0	0.0	0.0	132.5	1.1	e
3	Yumizen/Pentra	14	100.0	0.0	0.0	132.8	1.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	95.5	3.6	0.9	0.42	3.2	e
2	Advia	4	100.0	0.0	0.0	0.41	4.4	e*
3	Yumizen/Pentra	14	100.0	0.0	0.0	0.39	3.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	100.0	0.0	0.0	4.53	1.8	e
2	Advia	4	100.0	0.0	0.0	4.57	3.3	e
3	Yumizen/Pentra	14	92.9	0.0	7.1	4.51	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	98.1	1.9	0.0	5.56	5.6	e
2	Advia	4	100.0	0.0	0.0	4.96	6.0	e
3	Yumizen/Pentra	14	92.9	0.0	7.1	4.89	8.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	97.2	2.8	0.0	232.0	8.0	e
2	Advia	4	100.0	0.0	0.0	188.0	2.6	e
3	Yumizen/Pentra	14	92.9	0.0	7.1	221.6	10.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	98.2	1.8	0.0	3.13	7.3	e
2	Advia	4	100.0	0.0	0.0	2.93	5.7	e
3	Yumizen/Pentra	13	84.6	0.0	15.4	2.46	13.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lymphocytes



MQ tolerance : 25 %

Lymphocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	100.0	0.0	0.0	1.75	5.7	e
2	Advia	4	100.0	0.0	0.0	1.40	5.3	e
3	Yumizen/Pentra	13	92.3	0.0	7.7	1.89	8.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Monocytes



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	100.0	0.0	0.0	0.50	19.9	a
2	Advia	4	100.0	0.0	0.0	0.31	20.9	a
3	Yumizen/Pentra	13	92.3	0.0	7.7	0.36	28.3	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Eosinophils



MQ tolerance : 80 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	100.0	0.0	0.0	0.10	16.1	e
2	Advia	4	100.0	0.0	0.0	0.15	21.0	e*
3	Yumizen/Pentra	13	100.0	0.0	0.0	0.09	39.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Basophiles



MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	88.1	6.4	5.5	0.09	63.9	a
2	Advia	4	100.0	0.0	0.0	0.05	54.0	e*
3	Yumizen/Pentra	13	92.3	0.0	7.7	0.06	64.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	97	100.0	0.0	0.0	91.9	3.8	e
2	Advia	4	100.0	0.0	0.0	89.9	0.8	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	86.9	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	98	100.0	0.0	0.0	28.9	1.5	e
2	Advia	4	100.0	0.0	0.0	29.0	2.1	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	29.6	3.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	99	100.0	0.0	0.0	315	3.7	e
2	Advia	4	100.0	0.0	0.0	322	2.9	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	343	4.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	95	100.0	0.0	0.0	14.7	3.6	e
2	Yumizen/Pentra	9	100.0	0.0	0.0	14.0	11.2	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	89	97.8	0.0	2.2	0.04	50.8	e*

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	59	94.9	3.4	1.7	52.9	13.1	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe A



MQ tolerance : 15 %

Hämolyseindex Probe A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	23	100.0	0.0	0.0	88.83	6.4	e
2	Abbott	6	100.0	0.0	0.0	0.63	10.0	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Hämolyseindex Probe B



MQ tolerance : 15 %

Hämolyseindex Probe B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	23	82.7	13.0	4.3	15.68	10.3	e*
2	Abbott	6	100.0	0.0	0.0	0.11	6.9	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	24	83.3	12.5	4.2	15	32.5	a
2	miniiSed	4	75.0	0.0	25.0	1	0.0	e
3	Sarstedt Sedivette	19	100.0	0.0	0.0	7	25.2	a
4	Sarstedt Microvette	5	100.0	0.0	0.0	8	8.4	a
5	BD Seditainer	44	100.0	0.0	0.0	7	17.0	a
6	Other methods	19	94.7	0.0	5.3	7	24.7	a

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	7	100.0	0.0	0.0	16	10.2	a
2	BD Seditainer	4	100.0	0.0	0.0	16	6.3	a
3	Other methods	5	100.0	0.0	0.0	13	22.6	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	162.3	4.3	e*

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	0.4	4.4	e*

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	100.0	0.0	0.0	4.67	3.2	e

Leucocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	7.72	5.7	e

Trombocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	266.2	4.1	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	376	99.7	0.0	0.3	46.9	3.4	e
2	Cobas	36	97.2	0.0	2.8	52.3	6.0	e
3	Turbidimetry	14	78.6	0.0	21.4	54.5	3.2	e
4	Afinion	1136	99.7	0.1	0.2	53.9	4.6	e
5	NycoCard SingleTest-	63	81.0	9.5	9.5	52.2	12.1	e
6	Quick Read go	87	96.6	1.1	2.3	53.9	7.9	e
7	Eurolyser	80	75.0	7.5	17.5	63.3	13.4	e
8	Fuji Dri-Chem	11	81.8	0.0	18.2	55.7	10.5	e*
9	Autolyser/DiaSys	11	90.9	0.0	9.1	52.7	9.7	e*
10	Piccolo	6	83.3	0.0	16.7	74.7	12.4	e*
11	Celltac chemi	43	100.0	0.0	0.0	57.8	4.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	21	95.2	0.0	4.8	92.6	6.4	e

CRP



QUALAB tolerance : 21 %

CRP (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	15	93.3	0.0	6.7	52.4	9.1	e
2	Abbott	11	100.0	0.0	0.0	55.8	3.6	e
3	AQT 90 FLEX	6	100.0	0.0	0.0	53.5	3.9	e
4	Spotchem D-Concept	5	100.0	0.0	0.0	58.4	9.4	e*
5	Other methods	4	100.0	0.0	0.0	55.6	2.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	20	100.0	0.0	0.0	15.42	4.5	e
2	Nephelometry	4	100.0	0.0	0.0	15.35	3.1	e
3	Other methods	5	100.0	0.0	0.0	15.00	4.9	e*

IgA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	18	100.0	0.0	0.0	2.52	3.7	e
2	Nephelometry	5	100.0	0.0	0.0	2.67	1.4	e
3	Other methods	4	100.0	0.0	0.0	2.48	2.2	e

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	100.0	0.0	0.0	1.18	4.2	e
2	Nephelometry	4	100.0	0.0	0.0	1.16	5.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	93	9.3	e*
2	Cobas	6	100.0	0.0	0.0	128	9.1	e*

Alpha-1-Antitrypsin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	1.59	4.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	205	4.5	e
2	Other methods	5	100.0	0.0	0.0	146	2.0	e

Complement C3



QUALAB tolerance : 15 %

Complement C3 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	1.92	3.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

Complement C4 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.37	1.3	e
2	Other methods	15	100.0	0.0	0.0	0.35	7.1	e*

Haptoglobin



MQ tolerance : 25 %

Haptoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	27	100.0	0.0	0.0	1.61	3.4	e

Transferrin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	3.02	2.9	e

Beta-2 microglobuline



MQ tolerance : 25 %

Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	2.34	4.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	6	100.0	0.0	0.0	35.3	8.2	e*
2	Other methods	6	100.0	0.0	0.0	36.7	1.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	8	100.0	0.0	0.0	394.50	5.3	e
2	Other methods	4	100.0	0.0	0.0	310.00	1.1	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	100.0	0.0	0.0	270.76	7.3	e

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	3.4	1.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

free light chain kappa (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	5	100.0	0.0	0.0	9.39	5.3	e
2	Freelite	11	100.0	0.0	0.0	17.89	3.9	e

free light chain lambda



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	5	100.0	0.0	0.0	7.90	11.4	a
2	Freelite	10	100.0	0.0	0.0	16.41	5.1	e

IgE peanut qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.15	43.1	e*

IgE birch qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.20	28.3	e*

IgE cat qn



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	100.00	0.0	e

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	540	10.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE sx1 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	80.0	10.0	10.0	67.74	15.8	e*

IgE fx5 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	90.9	0.0	9.1	0.13	24.3	e*

IgE rx1qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	0.80	15.6	e*

IgE rx2 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	88.65	11.2	e*

IgE D. pteronyssinus qn



IgE D. pteronyssinus qn (kU/L)

QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	0.49	24.0	e*

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	5.12	6.1	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	61	9.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	138	91.4	4.3	4.3	45.6	9.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti deam. Gliadin IgA



MQ tolerance : 30 %
(< 2.00: +/- 1.00 U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	0.80	48.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgA



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	100.0	0.0	0.0	3.00	15.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP Lumira



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	12	100.0	0.0	0.0	88.7	8.7	e*

Albumine



QUALAB tolerance : 12 %
(< 30: +/- 4 g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	7	100.0	0.0	0.0	26	7.6	e*
2	Cobas	25	100.0	0.0	0.0	34	2.1	e
3	Abbott	11	100.0	0.0	0.0	30	3.2	e
4	Fuji Dri-Chem	250	98.4	0.0	1.6	40	4.0	e
5	Spotchem SP-4430	29	93.2	3.4	3.4	34	4.4	e
6	Spotchem D-Concept	226	97.8	1.8	0.4	36	4.9	e
7	Piccolo	64	98.4	0.0	1.6	31	4.9	e
8	Beckmann	5	100.0	0.0	0.0	32	4.3	e*
9	Skyla	4	100.0	0.0	0.0	32	1.6	e
10	Selectra Pro	11	100.0	0.0	0.0	33	4.3	e
11	Autolyser/DiaSys	8	100.0	0.0	0.0	33	3.8	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

Alkaline phosphatase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	13	100.0	0.0	0.0	332	2.4	e
2	Cobas	30	100.0	0.0	0.0	288	4.9	e
3	Reflotron	13	69.2	0.0	30.8	580	9.1	e*
4	Fuji Dri-Chem	1026	98.7	0.5	0.8	351	5.4	e
5	Spotchem SP-4430	93	91.4	5.4	3.2	238	8.4	e
6	Spotchem D-Concept	520	98.6	0.4	1.0	290	6.2	e
7	Beckman	6	83.3	16.7	0.0	359	10.8	e*
8	Dimension	4	100.0	0.0	0.0	294	2.2	e
9	Piccolo	55	98.2	1.8	0.0	377	4.9	e
10	Selectra Pro	15	93.3	0.0	6.7	353	7.5	e
11	Skyla	6	83.3	0.0	16.7	526	3.3	e
12	Autolyser/DiaSys	21	95.2	0.0	4.8	297	5.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Amylase



QUALAB tolerance : 18 %

Amylase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	357	3.1	e
2	Reflotron	5	100.0	0.0	0.0	324	8.3	e*
3	Fuji Dri-Chem	747	99.2	0.1	0.7	314	4.0	e
4	Spotchem SP-4430	65	93.8	6.2	0.0	172	8.7	e
5	Spotchem D-Concept	386	99.2	0.8	0.0	253	7.2	e
6	Skyla	5	100.0	0.0	0.0	636	2.6	e
7	Abbott	5	100.0	0.0	0.0	386	1.7	e
8	Beckman	4	100.0	0.0	0.0	393	6.2	e*
9	Piccolo	59	100.0	0.0	0.0	330	2.7	e
10	Selectra Pro	9	100.0	0.0	0.0	486	3.2	e
11	Autolyser/DiaSys	8	100.0	0.0	0.0	349	2.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	12	100.0	0.0	0.0	328	2.0	e
2	Cobas	14	100.0	0.0	0.0	336	2.1	e
3	Reflotron	25	96.0	0.0	4.0	294	4.4	e
4	Autolyser/DiaSys	11	100.0	0.0	0.0	320	3.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	17	94.1	5.9	0.0	83.2	11.2	e*
2	Cobas	29	100.0	0.0	0.0	79.1	4.4	e
3	Reflotron	13	76.9	7.7	15.4	83.5	8.8	e*
4	Fuji Dri-Chem	829	97.5	1.1	1.4	82.8	5.9	e
5	Spotchem SP-4430	81	84.0	7.4	8.6	97.6	9.0	e
6	Spotchem D-Concept	416	95.4	2.9	1.7	72.6	6.9	e
7	Dimension	4	100.0	0.0	0.0	96.8	3.2	e
8	Beckman	7	100.0	0.0	0.0	94.0	6.2	e*
9	Piccolo	62	90.3	6.5	3.2	74.4	8.2	e
10	Skyla	4	100.0	0.0	0.0	96.7	11.4	e*
11	Selectra Pro	15	86.7	13.3	0.0	76.2	10.6	e*
12	Autolyser/DiaSys	18	100.0	0.0	0.0	76.8	4.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Bilirubin direct



MQ tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser/DiaSys	8	100.0	0.0	0.0	53.8	5.1	e
2	Fuji Dri-Chem	27	81.5	3.7	14.8	51.1	7.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	2.80	2.8	e
2	Cobas	29	100.0	0.0	0.0	2.85	1.9	e
3	Fuji Dri-Chem	319	95.9	2.2	1.9	3.03	4.0	e
4	Spotchem SP-4430	14	100.0	0.0	0.0	2.72	4.2	e*
5	Spotchem D-Concept	79	91.1	5.1	3.8	2.05	5.2	e
6	Piccolo	56	98.2	0.0	1.8	2.87	3.5	e
7	Selectra Pro	7	100.0	0.0	0.0	2.83	3.1	e*
8	Autolyser/DiaSys	9	77.8	22.2	0.0	2.63	6.5	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

Calcium ISE (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	5	80.0	0.0	20.0	1.02	1.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	28	92.9	0.0	7.1	88	1.8	e
2	Cobas	19	94.7	0.0	5.3	85	2.0	e
3	Fuji Dri-Chem	938	97.8	1.5	0.7	98	1.8	e
4	Spotchem D-Concept	440	98.8	0.7	0.5	102	2.1	e
5	Standard chemistry	4	75.0	25.0	0.0	89	4.3	e*
6	Spotchem EL-SE 1520	78	88.5	7.7	3.8	106	3.2	e
7	Piccolo	27	96.3	3.7	0.0	90	2.7	e
8	iStat Chem8	5	100.0	0.0	0.0	97	2.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	2.44	5.3	e
2	Cobas	26	100.0	0.0	0.0	2.36	2.7	e
3	Reflotron	18	94.4	0.0	5.6	2.57	2.4	e
4	Fuji Dri-Chem	977	97.4	0.8	1.8	2.41	3.7	e
5	Spotchem SP-4430	89	94.4	4.5	1.1	2.52	4.8	e
6	Spotchem D-Concept	443	96.6	1.1	2.3	2.47	3.5	e
7	Piccolo	29	100.0	0.0	0.0	2.39	2.5	e
8	Cholestech LDX	256	99.6	0.0	0.4	2.59	0.2	e
9	Selectra Pro	14	78.6	14.3	7.1	2.50	4.8	e*
10	Autolyser/DiaSys	21	90.5	0.0	9.5	2.44	4.7	e
11	Other methods	4	100.0	0.0	0.0	2.59	0.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %
(< 0.40: +/- 0.09 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Wet chemistry, direc	6	100.0	0.0	0.0	0.80	4.7	e
2	Cobas	24	100.0	0.0	0.0	0.44	7.0	e
3	Reflotron	8	75.0	0.0	25.0	0.47	10.2	e*
4	Fuji Dri-Chem	943	98.9	0.1	1.0	0.83	4.3	e
5	Spotchem SP-4430	80	100.0	0.0	0.0	0.26	2.4	e
6	Spotchem D-Concept	423	99.1	0.0	0.9	0.26	1.4	e
7	Dimension	4	100.0	0.0	0.0	1.09	9.9	e*
8	Piccolo	28	85.8	7.1	7.1	0.53	12.4	e
9	Pentra/Selectra	13	76.9	0.0	23.1	0.96	8.8	e
10	Cholestech LDX	255	92.6	2.7	4.7	0.39	6.2	e
11	Architect	15	100.0	0.0	0.0	0.67	5.8	e
12	Autolyser/DiaSys	21	95.2	4.8	0.0	1.01	9.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	18	100.0	0.0	0.0	507	2.4	e
2	Cobas	27	100.0	0.0	0.0	481	1.5	e
3	Fuji Dri-Chem	668	98.2	0.9	0.9	540	5.5	e
4	Spotchem SP-4430	47	97.9	0.0	2.1	540	5.3	e
5	Spotchem D-Concept	306	88.3	8.8	2.9	498	9.5	e
6	Piccolo	22	100.0	0.0	0.0	478	3.2	e
7	Selectra Pro	9	100.0	0.0	0.0	549	4.5	e
8	Dimension	4	100.0	0.0	0.0	480	1.9	e
9	Autolyser/DiaSys	18	100.0	0.0	0.0	513	3.0	e
10	Other methods	4	100.0	0.0	0.0	510	3.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Selectra	6	50.0	33.3	16.7	1.4	18.7	e*
2	Standard chemistry	15	100.0	0.0	0.0	1.4	4.0	e
3	Roche, Cobas	15	100.0	0.0	0.0	1.6	2.8	e
4	Autolyser/DiaSys	12	75.0	0.0	25.0	1.7	6.6	e
5	Beckman	4	100.0	0.0	0.0	1.6	5.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Iron



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	18	4.2	e
2	Cobas	17	100.0	0.0	0.0	18	2.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	30	100.0	0.0	0.0	113	6.4	e
2	Reflotron	47	95.8	2.1	2.1	154	7.8	e
3	Fuji Dri-Chem	1131	99.6	0.0	0.4	152	4.8	e
4	Spotchem SP-4430	135	97.0	3.0	0.0	137	7.1	e
5	Spotchem D-Concept	592	98.7	0.8	0.5	142	7.4	e
6	Selectra/Biolis	4	100.0	0.0	0.0	112	3.9	e
7	Abbott	15	100.0	0.0	0.0	117	7.0	e
8	IFCC Beckmann	6	100.0	0.0	0.0	118	4.7	e
9	Piccolo	61	100.0	0.0	0.0	102	5.0	e
10	Skyla	5	80.0	0.0	20.0	120	7.5	e*
11	Selectra Pro	11	100.0	0.0	0.0	119	3.7	e
12	Autolyser/DiaSys	21	100.0	0.0	0.0	122	4.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Pulse	8	100.0	0.0	0.0	15.6	2.4	e
2	Standard chemistry	26	96.2	3.8	0.0	16.8	4.3	e
3	Cobas	33	100.0	0.0	0.0	16.6	3.1	e
4	Reflotron	47	87.2	4.3	8.5	17.3	4.7	e
5	Fuji Dri-Chem	1068	98.7	0.6	0.7	15.4	2.9	e
6	Spotchem SP-4430	118	91.6	5.9	2.5	16.2	5.0	e
7	Spotchem D-Concept	559	92.3	6.3	1.4	16.2	4.7	e
8	Dimension	4	100.0	0.0	0.0	17.0	1.8	e
9	Piccolo	74	100.0	0.0	0.0	16.3	1.0	e
10	Cholestech LDX	252	88.5	9.1	2.4	15.1	5.2	e
11	Selectra Pro	16	93.7	6.3	0.0	16.9	5.1	e*
12	Autolyser/DiaSys	19	89.5	10.5	0.0	15.9	5.1	e*
13	iStat Chem8	7	85.7	14.3	0.0	15.2	5.0	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	112	93.7	5.4	0.9	17.0	4.0	e
2	Accu-Chek Aviva	134	85.1	6.7	8.2	19.1	4.2	e
3	Accu-Chek Inform 2	922	98.5	1.1	0.4	20.1	3.5	e
4	Accu-Check Guide	265	93.2	3.8	3.0	16.9	3.8	e
5	Contour XT	1362	94.4	3.5	2.1	17.1	4.1	e
6	Skyla	6	100.0	0.0	0.0	16.8	4.1	e*
7	Statstrip/Xpress	100	100.0	0.0	0.0	15.3	2.6	e
8	Glucocard	11	72.7	9.1	18.2	26.3	5.0	e*
9	Hemocue 201+ P-equiv	113	92.9	1.8	5.3	20.0	3.2	e
10	Hemocue 201RT P-equi	126	96.8	0.0	3.2	19.8	2.8	e
11	CardioChek	4	75.0	25.0	0.0	23.8	7.1	e*
12	Freestyle Freedom li	4	100.0	0.0	0.0	18.9	1.6	e
13	Contour NEXT	32	90.6	6.3	3.1	17.2	4.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue 201+ (alt)	33	97.0	0.0	3.0	19.9	3.2	e
2	OneTouch Verio	21	100.0	0.0	0.0	16.6	2.3	e
3	Contour 2 (5s)	10	80.0	20.0	0.0	15.3	5.9	e*
4	Healthpro	25	72.0	12.0	16.0	24.9	6.8	e*
5	Mylife UNIO	480	95.2	4.8	0.0	20.1	3.9	e
6	mylife Pura	103	93.2	3.9	2.9	21.6	4.5	e
7	Alpha Check	16	37.4	18.8	43.8	21.5	8.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	100.0	0.0	0.0	555	2.4	e
2	Cobas	26	100.0	0.0	0.0	546	2.4	e
3	Reflotron	21	85.7	4.8	9.5	574	6.8	e*
4	Fuji Dri-Chem	1051	98.4	0.2	1.4	618	2.4	e
5	Spotchem SP-4430	112	95.5	3.6	0.9	482	5.3	e
6	Spotchem D-Concept	551	98.2	0.9	0.9	476	3.9	e
7	Piccolo	39	97.4	0.0	2.6	442	4.0	e
8	Skyla	5	100.0	0.0	0.0	523	1.6	e
9	Selectra Pro	16	100.0	0.0	0.0	550	3.0	e
10	Autolyser/DiaSys	20	95.0	5.0	0.0	511	5.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Urea



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	20.8	5.1	e
2	Cobas	27	100.0	0.0	0.0	19.9	2.4	e
3	Reflotron	8	100.0	0.0	0.0	21.1	6.4	e*
4	Fuji Dri-Chem	641	99.1	0.0	0.9	20.8	1.9	e
5	Spotchem SP-4430	62	95.2	3.2	1.6	21.4	5.9	e
6	Spotchem D-Concept	308	93.6	4.5	1.9	23.1	7.3	e
7	Piccolo	64	98.4	0.0	1.6	18.5	3.4	e
8	Skyla	6	100.0	0.0	0.0	19.2	7.4	e*
9	Selectra Pro	9	100.0	0.0	0.0	19.8	7.1	e*
10	Autolyser/DiaSys	17	100.0	0.0	0.0	20.2	4.6	e
11	Other methods	5	80.0	20.0	0.0	20.6	9.3	e*
12	iStat Chem8	6	83.3	0.0	16.7	25.5	8.1	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Potassium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	39	94.9	5.1	0.0	5.53	2.2	e
2	Cobas	29	100.0	0.0	0.0	5.54	1.4	e
3	Reflotron	40	75.0	15.0	10.0	5.81	4.2	e
4	Fuji Dri-Chem	1107	97.5	1.3	1.2	5.48	1.6	e
5	Spotchem D-Concept	560	98.4	0.2	1.4	4.74	1.7	e
6	Autolyser/DiaSys	9	88.9	11.1	0.0	5.53	2.9	e*
7	Spotchem EL-SE 1520	100	97.0	1.0	2.0	4.66	2.2	e
8	Piccolo	42	81.0	7.1	11.9	5.50	3.8	e
9	iStat Chem8	8	87.5	12.5	0.0	5.50	2.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

Creatinine (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	501	3.6	e
2	Cobas	30	100.0	0.0	0.0	486	3.0	e
3	Reflotron	73	94.5	0.0	5.5	528	6.5	e
4	Fuji Dri-Chem	1160	98.8	0.3	0.9	429	3.7	e
5	Spotchem SP-4430	154	99.4	0.0	0.6	297	2.7	e
6	Spotchem D-Concept	598	98.6	0.2	1.2	290	4.3	e
7	Enzymatic	11	100.0	0.0	0.0	514	3.9	e
8	Piccolo	69	100.0	0.0	0.0	480	2.8	e
9	Selectra Pro	17	88.2	0.0	11.8	485	3.7	e
10	Skyla	5	100.0	0.0	0.0	422	4.5	e
11	Autolyser/DiaSys	21	100.0	0.0	0.0	494	3.5	e
12	Other methods	4	100.0	0.0	0.0	520	2.9	e
13	EPOC	11	81.8	0.0	18.2	465	8.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine E



QUALAB tolerance : 18 %

Creatinine E (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	24	100.0	0.0	0.0	523	5.1	e
2	ABL700/800	12	100.0	0.0	0.0	493	6.7	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	59	98.3	0.0	1.7	7	7.0	e
2	Reflotron	23	91.4	4.3	4.3	7	9.1	e
3	Fuji Dri-Chem	428	90.4	3.3	6.3	9	9.2	e
4	Spotchem	276	90.6	1.8	7.6	14	8.7	e

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Reflotron	4	50.0	25.0	25.0	8	23.9	e*
2	Fuji Dri-Chem	35	94.3	0.0	5.7	10	14.8	e
3	Spotchem	15	93.3	0.0	6.7	16	13.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

eGFR MDRD



MQ tolerance : 30 %

eGFR MDRD ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	5	80.0	0.0	20.0	11	18.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	39	100.0	0.0	0.0	292	5.3	e
2	Cobas	12	100.0	0.0	0.0	299	3.0	e
3	Fuji Dri-Chem	127	95.3	0.8	3.9	249	5.3	e
4	Spotchem SP-4430	13	100.0	0.0	0.0	231	5.7	e
5	Spotchem D-Concept	42	97.6	2.4	0.0	245	6.0	e
6	Autolyser/DiaSys	7	100.0	0.0	0.0	298	5.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	20	100.0	0.0	0.0	1.58	2.8	e
2	Cobas	19	100.0	0.0	0.0	1.55	1.8	e
3	Fuji Dri-Chem	85	96.4	2.4	1.2	1.58	4.0	e
4	Spotchem D-Concept	38	100.0	0.0	0.0	1.32	4.1	e
5	Spotchem SP-4430	4	75.0	25.0	0.0	1.19	6.5	e*
6	Beckman	5	100.0	0.0	0.0	1.60	2.0	e
7	Piccolo	4	100.0	0.0	0.0	1.66	2.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	39	100.0	0.0	0.0	123	2.1	e
2	Cobas	29	100.0	0.0	0.0	121	0.9	e
3	Fuji Dri-Chem	1016	98.5	0.6	0.9	128	1.3	e
4	Spotchem D-Concept	489	99.0	0.2	0.8	121	1.3	e
5	Spotchem EL-SE 1520	84	100.0	0.0	0.0	117	1.8	e
6	Piccolo	39	97.4	2.6	0.0	125	2.2	e
7	iStat Chem8	7	100.0	0.0	0.0	123	0.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	22	100.0	0.0	0.0	2.2	3.6	e
2	Cobas	23	100.0	0.0	0.0	2.2	2.3	e
3	Fuji Dri-Chem	79	97.4	1.3	1.3	2.3	3.5	e
4	Spotchem D-Concept	12	100.0	0.0	0.0	2.2	4.4	e
5	Piccolo	8	100.0	0.0	0.0	2.6	3.4	e

12 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	46.1	2.5	e
2	Cobas	25	100.0	0.0	0.0	45.0	2.7	e
3	Fuji Dri-Chem	199	97.5	0.5	2.0	46.1	3.3	e
4	Spotchem SP-4430	26	96.2	3.8	0.0	46.8	5.9	e
5	Spotchem D-Concept	180	96.7	3.3	0.0	43.0	5.6	e
6	Piccolo	51	98.0	0.0	2.0	46.1	2.1	e
7	Skyla	5	100.0	0.0	0.0	46.0	2.9	e
8	Selectra Pro	8	87.5	12.5	0.0	45.5	5.2	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	27	100.0	0.0	0.0	204	4.6	e
2	Cobas	27	96.3	0.0	3.7	215	2.5	e
3	Reflotron	52	77.0	3.8	19.2	219	8.6	e
4	Fuji Dri-Chem	1141	97.9	1.1	1.0	161	4.2	e
5	Spotchem SP-4430	146	100.0	0.0	0.0	121	5.7	e
6	Spotchem D-Concept	590	99.7	0.0	0.3	123	3.8	e
7	Piccolo	75	100.0	0.0	0.0	153	3.1	e
8	Skyla	6	83.3	16.7	0.0	170	9.9	e*
9	Selectra Pro	16	100.0	0.0	0.0	175	5.6	e
10	Autolyser/DiaSys	21	100.0	0.0	0.0	170	6.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

Alanine aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	22	100.0	0.0	0.0	147	4.8	e
2	Cobas	30	100.0	0.0	0.0	149	3.9	e
3	Reflotron	39	87.2	5.1	7.7	136	8.2	e
4	Fuji Dri-Chem	1154	96.0	2.4	1.6	155	6.9	e
5	Spotchem SP-4430	148	98.6	1.4	0.0	134	6.8	e
6	Spotchem D-Concept	599	97.7	2.0	0.3	119	6.6	e
7	Piccolo	73	98.6	1.4	0.0	142	6.1	e
8	Skyla	6	66.6	16.7	16.7	162	11.9	e*
9	Selectra Pro	16	93.7	6.3	0.0	164	7.2	e
10	Autolyser/DiaSys	21	95.2	0.0	4.8	159	5.2	e
11	Other methods	5	100.0	0.0	0.0	167	1.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Triglycerides



QUALAB tolerance : 18 %
(< 1.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	1.30	7.8	e
2	Cobas	26	100.0	0.0	0.0	1.36	3.2	e
3	Reflotron	11	63.6	9.1	27.3	2.25	11.1	e*
4	Fuji Dri-Chem	963	97.5	0.4	2.1	1.65	5.0	e
5	Spotchem SP-4430	85	100.0	0.0	0.0	0.96	5.9	e
6	Spotchem D-Concept	433	97.9	0.5	1.6	1.07	4.3	e
7	Piccolo	27	100.0	0.0	0.0	1.62	4.2	e
8	Cholestech LDX	257	98.4	0.8	0.8	1.20	5.0	e
9	Selectra Pro	13	92.3	0.0	7.7	1.36	6.4	e
10	Autolyser/DiaSys	21	95.2	4.8	0.0	1.28	8.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Integra 800/40	4	100.0	0.0	0.0	1.89	1.2	e
2	Other methods	19	94.7	5.3	0.0	2.00	5.5	e

Lactate



QUALAB tolerance : 18 %

Lactate (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	100.0	0.0	0.0	5.64	4.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

HbA1c sample A



QUALAB tolerance : 9 %
(< 5.0: +/- 0.5 %)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	5.3	4.0	e
2	HPLC	8	100.0	0.0	0.0	5.3	1.7	e
3	Afinion	547	98.8	0.5	0.7	5.3	2.8	e
4	Cobas b101	179	97.2	2.8	0.0	5.1	3.6	e
5	DCA2000/Vantage	128	91.4	6.3	2.3	5.5	4.1	e
6	Celltac chemi	21	100.0	0.0	0.0	4.8	3.1	e
7	NycoCard	8	87.5	0.0	12.5	5.3	4.2	e*
8	Eurolyser	8	75.0	0.0	25.0	5.5	3.8	e*
9	A1c Now	231	92.7	5.6	1.7	5.2	5.0	e
10	AFIAS	92	97.8	0.0	2.2	5.1	3.7	e
11	Others	27	96.3	3.7	0.0	5.4	4.2	e
12	Spinit	18	100.0	0.0	0.0	5.6	3.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %
(< 5.0: +/- 0.5 %)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	18	100.0	0.0	0.0	5.3	4.7	e*
2	HPLC	9	100.0	0.0	0.0	5.4	2.4	e
3	Afinion	768	99.1	0.8	0.1	5.4	2.9	e
4	Cobas b101	189	97.9	2.1	0.0	5.1	3.6	e
5	DCA2000/Vantage	179	95.5	3.4	1.1	5.6	4.2	e
6	Celltac chemi	14	100.0	0.0	0.0	4.7	2.3	e
7	NycoCard	7	71.4	14.3	14.3	5.8	7.5	e*
8	Eurolyser	5	100.0	0.0	0.0	5.6	2.8	e*
9	A1c Now	4	100.0	0.0	0.0	5.5	5.5	a
10	AFIAS	120	95.0	5.0	0.0	5.0	4.7	e
11	Spinit	12	91.7	8.3	0.0	5.6	4.3	e*
12	Others	21	81.0	19.0	0.0	5.4	5.9	e*
13	Quick Read go	4	100.0	0.0	0.0	5.7	3.8	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	100.0	0.0	0.0	2.86	2.8	e
2	ABL80 FLEX	4	100.0	0.0	0.0	2.93	5.8	e*
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	3.05	7.0	e*
4	ABL90 FLEX / PLUS	114	99.1	0.0	0.9	3.05	2.2	e
5	Cobas b 123	14	100.0	0.0	0.0	3.02	1.9	e
6	Cobas b 221	7	100.0	0.0	0.0	2.98	3.4	e
7	GEM	8	100.0	0.0	0.0	2.80	1.9	e
8	iStat	45	95.6	2.2	2.2	2.60	4.1	e
9	EPOC	51	74.5	9.8	15.7	2.46	7.7	e
10	IL	4	100.0	0.0	0.0	2.80	1.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	104	94.3	1.9	3.8	9.80	5.3	e
2	ABL80 FLEX	4	75.0	25.0	0.0	9.00	10.4	e*
3	ABL80 FLEX CO-OX / O	5	60.0	20.0	20.0	7.80	10.8	e*
4	ABL90 FLEX / PLUS	115	83.5	1.7	14.8	7.36	4.4	e
5	Cobas b 123	16	100.0	0.0	0.0	8.80	4.4	e
6	Cobas b 221	4	100.0	0.0	0.0	12.13	6.5	e*
7	GEM	8	100.0	0.0	0.0	8.95	7.0	e*
8	iStat	42	57.1	14.3	28.6	11.46	10.4	e
9	EPOC	51	76.5	7.8	15.7	9.77	8.4	e
10	IL	4	100.0	0.0	0.0	9.45	3.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	99.1	0.0	0.9	7.57	0.1	e
2	ABL80 FLEX	4	100.0	0.0	0.0	7.61	0.2	e*
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	7.60	0.2	e
4	ABL90 FLEX / PLUS	115	99.1	0.0	0.9	7.59	0.1	e
5	Cobas b 123	15	100.0	0.0	0.0	7.57	0.3	e
6	Cobas b 221	8	100.0	0.0	0.0	7.58	0.3	e
7	GEM	8	100.0	0.0	0.0	7.64	0.2	e
8	iStat	46	100.0	0.0	0.0	7.65	0.1	e
9	EPOC	50	96.0	2.0	2.0	7.63	0.3	e
10	IL	4	100.0	0.0	0.0	7.64	0.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	10	100.0	0.0	0.0	14.5	3.4	e*
2	iStat	10	90.0	0.0	10.0	13.8	1.5	a
3	EPOC	40	97.5	0.0	2.5	14.2	3.4	e
4	ABL700/800	96	100.0	0.0	0.0	14.1	2.1	e
5	ABL90 FLEX / PLUS	100	100.0	0.0	0.0	13.6	2.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	98	98.0	0.0	2.0	192.3	1.7	e
2	ABL90 FLEX / PLUS	100	100.0	0.0	0.0	192.5	0.5	e
3	ABL80 FLEX CO-OX / O	6	100.0	0.0	0.0	191.0	1.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	5.5	1.6	e*
2	Cobas b 123	19	100.0	0.0	0.0	5.4	0.8	e
3	iStat	17	100.0	0.0	0.0	5.3	1.6	e
4	EPOC	43	79.0	16.3	4.7	4.8	4.1	e
5	ABL700/800	97	100.0	0.0	0.0	5.5	1.2	e
6	ABL90 FLEX / PLUS	109	100.0	0.0	0.0	5.4	1.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

Sodium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	123.0	0.4	e
2	Cobas b 123	19	100.0	0.0	0.0	122.4	0.7	e
3	iStat	17	100.0	0.0	0.0	124.9	0.4	e
4	EPOC	40	100.0	0.0	0.0	120.4	1.3	e
5	ABL700/800	97	100.0	0.0	0.0	126.4	0.8	e
6	ABL90 FLEX / PLUS	108	100.0	0.0	0.0	126.1	0.3	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	8	100.0	0.0	0.0	70.0	0.5	e
2	EPOC	13	100.0	0.0	0.0	72.1	2.8	e*
3	ABL700/800	91	95.6	3.3	1.1	68.0	2.9	e
4	ABL90 FLEX / PLUS	103	99.0	0.0	1.0	63.6	1.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	0.27	7.8	e*
2	Cobas b123	12	100.0	0.0	0.0	0.16	28.5	e*
3	Roche, Cobas	7	100.0	0.0	0.0	0.27	27.2	e*
4	iStat	13	100.0	0.0	0.0	0.31	0.0	e
5	EPOC	38	92.1	0.0	7.9	0.26	4.9	e
6	ABL700/800	97	100.0	0.0	0.0	0.37	4.2	e
7	ABL90 FLEX / PLUS	106	99.1	0.0	0.9	0.37	2.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	6	100.0	0.0	0.0	20.900	0.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

Lactate-BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	11.85	1.8	e
2	Cobas b123	8	100.0	0.0	0.0	10.50	5.2	e
3	Roche, Cobas	6	100.0	0.0	0.0	12.23	4.6	e
4	IL	4	100.0	0.0	0.0	11.05	2.8	e
5	EPOC	37	78.4	10.8	10.8	7.47	11.3	e
6	iStat	14	100.0	0.0	0.0	10.94	1.7	e
7	ABL700/800	100	100.0	0.0	0.0	10.39	4.2	e
8	ABL90 FLEX / PLUS	108	100.0	0.0	0.0	10.46	2.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	16	100.0	0.0	0.0	98.688	0.6	e
2	ABL700/800	87	98.9	0.0	1.1	70.094	0.1	e
3	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	70.084	0.1	e
4	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	70.000	0.1	e

FO2Hb OR



MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	97.7	0.0	2.3	48.871	0.2	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	48.941	0.2	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	49.000	0.1	e

FCOHb OR



MQ tolerance : 20 %

FCOHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	97.7	0.0	2.3	20.272	1.0	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	20.162	0.7	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	20.000	1.0	e

FMetHb OR



MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	97.7	0.0	2.3	10.001	0.7	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	9.985	1.3	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	10.000	0.0	e

FHbF OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	4	75.0	0.0	25.0	53.000	8.0	e*
2	ABL90 FLEX / PLUS	37	100.0	0.0	0.0	52.432	3.1	e

Bilirubin OR



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	5	80.0	0.0	20.0	442.0	0.3	e
2	ABL90 FLEX / PLUS	31	93.5	0.0	6.5	444.1	0.5	e

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	13	100.0	0.0	0.0	4037.5	10.1	e
2	Vidas	12	100.0	0.0	0.0	4384.5	6.9	e
3	Architect High Sensi	10	100.0	0.0	0.0	1565.6	7.6	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

Troponin T (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	10	100.0	0.0	0.0	878.56	6.6	e
2	Cobas hs STAT	11	100.0	0.0	0.0	886.39	4.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Myoglobin



QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	79.7	4.0	e
2	Abbott	5	100.0	0.0	0.0	95.0	9.0	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	8.1	8.4	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	271.0	12.4	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	10	90.0	0.0	10.0	507.2	10.0	e
2	VIDAS	10	100.0	0.0	0.0	138.7	8.9	e
3	Other methods	4	75.0	25.0	0.0	282.0	13.5	e*
4	Cobas E / Elecsys	20	100.0	0.0	0.0	211.0	7.6	e
5	Abbott	8	100.0	0.0	0.0	246.6	7.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	25	100.0	0.0	0.0	4.41	3.7	e
2	Abbott	11	100.0	0.0	0.0	3.41	4.8	e
3	VIDAS	14	100.0	0.0	0.0	4.49	5.4	e
4	Dimension	4	100.0	0.0	0.0	3.74	3.8	e
5	AFIAS	21	66.7	9.5	23.8	6.89	9.9	e*
6	Other methods	5	80.0	0.0	20.0	4.04	8.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	100.0	0.0	0.0	1.6	5.8	e*
2	Abbott	4	100.0	0.0	0.0	2.7	4.5	e

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	80.0	20.0	0.0	139	14.6	e*
2	Abbott	4	100.0	0.0	0.0	129	4.6	e

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	10.1	3.5	e
2	Abbott	10	100.0	0.0	0.0	8.1	4.8	e
3	VIDAS	7	100.0	0.0	0.0	8.5	4.5	e
4	Other methods	4	50.0	25.0	25.0	12.3	21.8	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	27.9	2.7	e
2	Abbott	11	100.0	0.0	0.0	20.5	4.9	e
3	VIDAS	8	100.0	0.0	0.0	26.5	3.6	e
4	Other methods	8	75.0	12.5	12.5	23.3	11.1	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	10.5	5.7	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	10.1	12.7	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

Estradiol (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	759	3.4	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	1109	9.8	e*
3	Abbott	6	100.0	0.0	0.0	714	5.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	14	100.0	0.0	0.0	28.8	3.5	e
2	Abbott	5	100.0	0.0	0.0	32.5	2.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	18	100.0	0.0	0.0	396	4.3	e
2	Abbott	5	100.0	0.0	0.0	390	3.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	24.5	4.3	e
2	Abbott	5	100.0	0.0	0.0	18.2	5.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

DHEAS



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	4.54	6.0	e
2	Abbott	4	100.0	0.0	0.0	3.91	4.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	16.9	5.1	e
2	Abbott	6	100.0	0.0	0.0	11.0	5.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	13.8	4.6	e
2	Architect	7	100.0	0.0	0.0	13.8	3.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactine



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	12	100.0	0.0	0.0	17.8	6.7	e
2	Abbott	4	100.0	0.0	0.0	15.5	7.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Insulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	13	100.0	0.0	0.0	359	8.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	9.93	6.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Freies Testosteron



MQ tolerance : 25 %

Freies Testosteron (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	20.1	12.9	e*
2	Other methods	4	100.0	0.0	0.0	28.0	8.4	e*

IGF-1



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	7	100.0	0.0	0.0	94	9.4	e*
2	Other methods	6	100.0	0.0	0.0	57	10.2	e*

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1288	94.3	4.5	1.2	225.26	11.7	e

D-dimer CR



QUALAB tolerance : 21 %

D-dimer CR (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1282	77.6	15.4	7.0	0.47	13.9	e
2	Lumira Dx	9	55.6	22.2	22.2	0.69	15.7	e*

CKMB- K8



MQ tolerance : 40 %

CKMB- K8 (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	9	100.0	0.0	0.0	16.0	8.5	e

NT-proBNP CR



QUALAB tolerance : 27 %

NT-proBNP CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	809	82.0	12.4	5.6	171	17.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	13	92.3	7.7	0.0	3.45	6.8	e*

PO2 CCA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	13	92.3	0.0	7.7	18.80	4.3	e

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	12	83.4	8.3	8.3	7.61	0.4	e*

Potassium CCA



QUALAB tolerance : 6 %

Potassium CCA (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	7	100.0	0.0	0.0	6.0	1.1	e

Sodium CCA



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	6	100.0	0.0	0.0	162.3	2.3	e*

Calcium CCA



MQ tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	75.0	0.0	25.0	0.78	2.0	e

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	4	100.0	0.0	0.0	35.45	6.5	e*
2	Beckman	6	100.0	0.0	0.0	33.50	8.3	e*
3	Cobas E / Elecsys	21	100.0	0.0	0.0	36.93	7.3	e
4	Abbott	13	100.0	0.0	0.0	35.48	4.2	e
5	Mini Vidas	7	100.0	0.0	0.0	25.50	10.7	e*
6	AFIAS	30	96.7	3.3	0.0	32.21	11.6	e
7	Eurolyser	8	37.5	0.0	62.5	27.25	2.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %
(< 200.00: +/- 42.00 pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	189.00	9.6	e*
2	Cobas E / Elecsys	18	100.0	0.0	0.0	202.08	7.3	e
3	Abbott	11	90.9	9.1	0.0	207.00	16.7	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %

Folate (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	44.65	2.2	e
2	Cobas E / Elecsys	20	100.0	0.0	0.0	49.08	10.0	e
3	Abbott	10	100.0	0.0	0.0	46.70	3.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	39.0	8.8	e
2	Other methods	25	100.0	0.0	0.0	31.8	3.9	e

Bilirubin total Neo



QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	88	6.2	e
2	Dimension	4	100.0	0.0	0.0	99	3.5	e

Bilirubin direct



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	54	7.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin neonatal



QUALAB tolerance : 18 %

Bilirubin neonatal (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	10	100.0	0.0	0.0	103	7.8	e*
2	Other methods	13	84.6	0.0	15.4	121	2.1	e

PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	19	94.7	5.3	0.0	4.31	7.7	e
2	Abbott	7	100.0	0.0	0.0	4.20	5.4	e
3	AFIAS	14	100.0	0.0	0.0	4.14	6.9	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	11	100.0	0.0	0.0	1.08	4.5	e
2	Abbott	5	100.0	0.0	0.0	1.14	4.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	100.0	0.0	0.0	13.2	5.7	e
2	Abbott	6	100.0	0.0	0.0	18.9	4.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	63.6	3.8	e
2	Abbott	4	100.0	0.0	0.0	96.6	4.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	28.0	2.5	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	11	90.9	9.1	0.0	55.5	15.5	d
2	Abbott	5	100.0	0.0	0.0	61.5	3.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	105.0	11.5	e*
2	Abbott	4	100.0	0.0	0.0	101.1	2.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 25 %

HCG qn (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	92.3	7.7	0.0	137.2	9.2	e
2	VIDAS	9	100.0	0.0	0.0	56.6	11.9	e*
3	Architect	8	100.0	0.0	0.0	136.7	5.8	e
4	AFIAS	6	83.3	0.0	16.7	212.5	17.3	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	48.0	1.2	e

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	1.42	3.0	e

NSE



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	4.9	11.2	d

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	68.2	4.6	e
2	Other methods	4	75.0	0.0	25.0	80.6	3.8	e

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	25	100.0	0.0	0.0	51.8	5.5	e
2	Cobas/Roche	7	100.0	0.0	0.0	40.0	2.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol PTS



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	20	30.0	0.0	70.0	3.78	7.0	e*

Cholesterol HDL PTS



QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	19	57.9	10.5	31.6	1.28	17.2	e*

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	19	36.9	10.5	52.6	1.30	13.6	e*

C-Peptid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	7.82	2.8	e
2	Other methods	5	100.0	0.0	0.0	6.45	8.7	a

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	26.72	9.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Procalcitonin



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	27.60	3.5	e
2	Cobas	14	100.0	0.0	0.0	22.88	4.1	e
3	VIDAS	13	100.0	0.0	0.0	17.75	8.9	e
4	Liaison	4	75.0	0.0	25.0	34.10	9.3	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

Parathyroid hormone (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	9	100.0	0.0	0.0	6.8	9.5	e*
2	Cobas	11	100.0	0.0	0.0	5.5	5.7	e
3	Abbott	5	100.0	0.0	0.0	13.0	4.7	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	22	95.5	0.0	4.5	316	1.6	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	3.8	1.6	e

Sodium-K22



QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	133	0.9	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	6.0	2.2	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.6	6.2	e

Osmotic Gap



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	10	90.0	0.0	10.0	32.9	12.5	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Digoxin



QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	10	100.0	0.0	0.0	3.41	9.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	75.0	25.0	0.0	79	18.1	e*

Phenobarbital



MQ tolerance : 25 %

Phenobarbital (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	190	9.2	e*

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	17.6	4.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

Valproat (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	664.0	5.9	e

Carbamazepin



MQ tolerance : 24 %

Carbamazepin (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	48.0	5.9	e

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	3.77	6.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Ethanol



QUALAB tolerance : 18 %

Ethanol (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	5	80.0	0.0	20.0	28.6	3.1	e
2	Abbott	5	80.0	20.0	0.0	28.2	10.6	e*
3	Roche, Cobas	21	100.0	0.0	0.0	27.6	4.8	e

Ammonia



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	120.5	7.4	e*
2	all Participants	5	100.0	0.0	0.0	138.5	10.4	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Calprotectin



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	16	81.2	0.0	18.8	172	20.6	a
2	Bühlmann Quantum Blu	5	60.0	0.0	40.0	159	11.3	a
3	Liaison	23	82.6	8.7	8.7	72	21.8	a

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	287	99.7	0.0	0.3	7.09	2.5	e
2	Afinion	424	98.8	0.5	0.7	7.08	3.6	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	284	94.0	0.4	5.6	1.60	4.0	e
2	Afinion	419	92.2	0.2	7.6	1.42	5.2	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	285	99.3	0.0	0.7	2.63	2.4	e
2	Afinion	425	99.3	0.5	0.2	2.47	5.5	e

Troponin I S



QUALAB tolerance : 24 %

Troponin I S (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	245	88.9	3.3	7.8	435.41	11.3	e

D-dimer qn S



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	245	81.3	6.9	11.8	0.60	11.7	e

NT-proBNP S



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS (Gen. 1)	21	100.0	0.0	0.0	4273.0	9.2	e
2	AFIAS	166	94.6	2.4	3.0	937.9	11.0	e

Homocystein



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	4	100.0	0.0	0.0	12.3	3.4	e
2	all Participants	5	80.0	20.0	0.0	9.5	17.5	e*

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	33.2	4.4	e
2	Beckman	5	100.0	0.0	0.0	33.0	2.1	e
3	Cobas	24	100.0	0.0	0.0	35.1	3.0	e
4	Fuji Dri-Chem	171	98.8	0.6	0.6	43.4	5.8	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Bicarbonat



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	16.0	6.3	e*
2	Other methods	4	100.0	0.0	0.0	15.0	6.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholinesterase



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	6.4	3.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose CSF



QUALAB tolerance : 9 %
(< 3.30: +/- 0.30 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	2.40	2.1	e
2	Other methods	12	100.0	0.0	0.0	2.39	2.0	e

Lactate CSF



QUALAB tolerance : 18 %

Lactate CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	2.90	2.6	e
2	Other methods	10	90.0	0.0	10.0	2.95	2.0	e

Protein CSF



QUALAB tolerance : 15 %

Protein CSF (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	0.65	4.4	e
2	Other methods	10	100.0	0.0	0.0	0.65	3.1	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	290.00	4.2	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CDT



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	1.61	15.1	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	12.6	8.2	e

Totalprotein E



MQ tolerance : 12 %

Totalprotein E (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	100.0	0.0	0.0	69.3	3.0	e

Albumin E



MQ tolerance : 12 %

Albumin E (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	27	100.0	0.0	0.0	62.9	5.0	e

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	10	100.0	0.0	0.0	2.2	10.8	e
2	capillary electropho	17	94.1	5.9	0.0	3.8	11.8	e

alpha-2-Globuline



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	27	96.3	3.7	0.0	9.4	10.2	e

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	15	100.0	0.0	0.0	9.7	11.2	e

Beta-1-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	14	100.0	0.0	0.0	6.7	15.0	e*

Beta-2-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	10	100.0	0.0	0.0	3.3	14.8	a

gamma-Globuline



MQ tolerance : 30 %

gamma-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	19	94.7	5.3	0.0	14.4	12.1	e

Gamma-Globuline+P



MQ tolerance : 30 %

Gamma-Globuline+P (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	12.1	4.1	e

Immunfixation



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	23	100.0	0.0	0.0	3	0.0	e

Folate in Erythrocytes



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	7	71.4	0.0	28.6	105	11.9	e
2	Abbott	5	100.0	0.0	0.0	178	15.2	e*
3	Roche, Cobas	20	100.0	0.0	0.0	1210	21.2	a
4	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	371	20.0	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Gallensäure



MQ tolerance : 30 %
(< 5.0: +/- 1.5 µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	8	87.5	0.0	12.5	5.1	22.0	a
2	all Participants	17	94.1	5.9	0.0	3.3	15.7	a

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	14	92.9	0.0	7.1	13.2	36.5	e*

Troponin Triage



QUALAB tolerance : 24 %

Troponin Triage (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	58	96.6	1.7	1.7	474.00	10.5	e
2	Triage SOB/Cardiac	5	60.0	0.0	40.0	10.00	0.0	e
3	Triage Next Gen	8	50.0	0.0	50.0	20.00	0.0	e

NT-pro BNP

QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	37	94.6	0.0	5.4	139	13.0	e

D-dimer Triage



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	65	33.9	12.3	53.8	228.20	17.1	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	5	100.0	0.0	0.0	70.1	7.7	e*
2	Cobas	15	86.7	13.3	0.0	64.6	13.4	e*
3	VIDAS	6	100.0	0.0	0.0	61.0	5.5	e
4	Other methods	12	75.0	8.3	16.7	64.2	17.6	e*
5	Architect	10	100.0	0.0	0.0	66.9	6.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	100.0	0.0	0.0	16.3	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Inhibin B



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	196.6	5.8	e

Calcitonin



MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	4	100.0	0.0	0.0	5.2	5.0	e
2	Other methods	7	100.0	0.0	0.0	18.8	7.0	e

IGF-BP3



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	3.34	3.2	e
2	all Participants	4	100.0	0.0	0.0	3.70	12.1	a

Renin



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	66.1	8.8	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Aldosteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	43.3	21.4	a

Anti Thyreoglobulin



MQ tolerance : 25 %

Anti Thyreoglobulin (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	4	100.0	0.0	0.0	275	11.4	e*
2	Alinity	6	100.0	0.0	0.0	111	7.6	e*
3	Cobas	9	100.0	0.0	0.0	648	6.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	85	1.9	e
2	Cobas	10	90.0	0.0	10.0	149	13.4	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	4.18	14.2	e*
2	Roche, Cobas	7	100.0	0.0	0.0	2.70	4.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine WB



QUALAB tolerance : 18 %

Creatinine WB (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	64	54.7	17.2	28.1	66	15.8	e

IL6



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	482.5	3.4	e

Pankreas Elastase



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	9	88.9	0.0	11.1	158	18.6	a

Copeptin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Kryptor	4	100.0	0.0	0.0	5.2	4.7	e

Occult blood qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	7	100.0	0.0	0.0	327	20.4	a

Calcium-Urine



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	100.0	0.0	0.0	2.64	1.5	e
2	Abbott	7	100.0	0.0	0.0	2.55	2.1	e
3	Other methods	6	100.0	0.0	0.0	2.70	4.6	e*

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	195	2.0	e
2	Roche, Cobas	12	91.7	0.0	8.3	189	3.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Glucose-Urine



QUALAB tolerance : 9 %

Glucose-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	21	100.0	0.0	0.0	16.3	1.9	e

Magnesium-Urine



MQ tolerance : 12 %

Magnesium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	3.70	3.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	19	100.0	0.0	0.0	803	0.7	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	95.7	4.3	0.0	15.8	4.7	a

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	71	3.1	e

Protein-Urine



QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	17	100.0	0.0	0.0	512.9	2.9	e
2	Standard chemistry	16	100.0	0.0	0.0	650.8	2.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	167	2.0	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	30	100.0	0.0	0.0	258	5.0	e

Uric Acid-Urine



MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	100.0	0.0	0.0	1.11	3.6	e

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	7	100.0	0.0	0.0	1.023	0.1	e

Ethylglucuronid



MQ tolerance : 25 %
(< 0.10: +/- 0.10 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	25.0	0.0	75.0	0.02	0.0	a

Creatinine U



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	110.0	3.2	a
2	Roche, Cobas	13	100.0	0.0	0.0	99.1	3.8	a
3	Aution	5	80.0	0.0	20.0	109.3	35.9	a
4	AFIAS	16	93.7	0.0	6.3	113.5	7.1	a
5	Afinion	481	97.9	0.4	1.7	110.1	9.7	a
6	Sysmex U	18	100.0	0.0	0.0	112.9	31.3	a
7	Turbidimetry	7	100.0	0.0	0.0	109.3	14.8	a
8	DCA2000/Vantage	149	95.9	0.7	3.4	105.5	8.0	a
9	Siemens Clinitek	21	100.0	0.0	0.0	109.3	30.2	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinin Urin



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	DCA2000/Vantage	146	95.2	2.1	2.7	4.9	7.1	e
2	Afinion	477	97.3	0.2	2.5	4.3	5.0	e
3	Standard chemistry	45	97.8	0.0	2.2	4.5	5.6	e
4	Sysmex U	15	93.3	0.0	6.7	4.4	0.1	e
5	Aution	5	40.0	0.0	60.0	4.4	0.0	a
6	Siemens Clinitek	20	20.0	0.0	80.0	4.4	0.0	a
7	Other methods	5	80.0	0.0	20.0	4.4	5.6	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)